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Abstract
Despite improvements in terms of sequence quality and price per basepair, Sanger sequencing remains restricted to
screening of individual disease genes. The development of massively parallel sequencing (MPS) technologies heralded an
era in which molecular diagnostics for multigenic disorders becomes reality. Here, we outline different PCR amplification
based strategies for the screening of a multitude of genes in a patient cohort. We performed a thorough evaluation in terms
of set-up, coverage and sequencing variants on the data of 10 GS-FLX experiments (over 200 patients). Crucially, we
determined the actual coverage that is required for reliable diagnostic results using MPS, and provide a tool to calculate the
number of patients that can be screened in a single run. Finally, we provide an overview of factors contributing to false
negative or false positive mutation calls and suggest ways to maximize sensitivity and specificity, both important in a
routine setting. By describing practical strategies for screening of multigenic disorders in a multitude of samples and
providing answers to questions about minimum required coverage, the number of patients that can be screened in a single
run and the factors that may affect sensitivity and specificity we hope to facilitate the implementation of MPS technology in
molecular diagnostics.
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Introduction
A multitude of laboratory technologies for the detection of DNA
mutations have been developed over the last decades. In current
diagnostic settings, most frequently a combination of a mutation
scanning technique, followed by Sanger sequencing of the
abnormal DNA fragments is used. Well known examples of
widely used methods to identify the aberrant fragments are single
strand conformation polymorphism (SSCP), conformation sensi-
tive gel electrophoresis (CSGE), high performance liquid chroma-
tography (HPLC) and more recently high resolution melting curve
analysis (HRMCA) [1,2,3,4]. Despite its higher cost, Sanger
sequencing [5] of DNA fragments remains the preferred method
for mutation analysis because of its superior sensitivity and
specificity and the detailed sequence information that can be
obtained in a single step approach. Improvements on sequencing
chemistries, instruments and data analysis software, as well as
increases in throughput and reductions in cost resulted in the
adoption of this technology for routine mutation analysis for
monogenic diseases. However, expansion of molecular diagnostics
to the realm of multigenic disorders requires the implementation
of new methods with increased mutation detection efficiency but
without a decrease in cost efficiency. Massively parallel sequencing
(MPS) technologies (see [6,7] for an overview) are an interesting
alternative because of their higher throughput and lower cost per
base as compared to Sanger sequencing. In addition, throughput
and cost for MPS technologies per base are rapidly evolving (from
0.1 Gb per run for the Roche Genome Sequencer at the end of
2006 to 150–300 Gb per run for Illumina’s HiSeq2000 and ABI’s
5500XL platform in 2011) at a speed vastly surpassing the
evolution rate seen in semiconductor industries (Moore’s law).
In order for MPS to take over the role of Sanger sequencing and
to evolve into the method of choice for next generation molecular
diagnostics (NGMD), a number of hurdles need to be taken and
questions be answered. The goal of this paper is to remove a
number of these obstructions by describing strategies which enable
mutation analysis through MPS, by presenting tools for determi-
nation of the required coverage and the number of patients who
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25531can be screened in a single run, and by listing possible sources of
false negative or false positive mutation calls along with possible
solutions. The guidelines and tools provided in this study were
formulated or calculated based on pyrosequencing data obtained
on the GS-FLX instrument (454-Roche), but may provide better
insights into applications with other MPS chemistries as well.
Materials and Methods
Generation of sequencing data
Sample preparation. The data presented in this article are
derived from 10 GS-FLX sequencing runs (using both Standard
and Titanium chemistries) on samples prepared with different
approaches. In total over 200 patient samples were evaluated in
these 10 experiments. To pool different patients in a single
experiment multiplex identifier (MID)-tags were attached on all
patients’ samples. Different approaches were evaluated to attach
these tags:
Approach 1: the samples investigated for recessive congenital
deafness (15 genes: GJB2, SLC26A4, MYO15A, OTOF, CDH23,
TMC1, TMPRSS3, TECTA, TRIOBP, TMIE, PJVK, ESPN, PCDH15,
ESRRB, MYO7A - 643 amplicons) were prepared with PCR (Kapa
Taq kit (Sopachem)) followed by an adapter ligation approach. All
PCR products for a given sample are pooled, thereby reducing the
number of parallel reactions in the next step from the number of
sample-amplicon combination (SAC) to the number of samples.
The next step involves ligation of adapters containing the sequencing
recognition sites (A & B) followed by a sample specific barcode
(ligation was performed according to GS FLX Shotgun DNA
library preparation quick guide). Once MID containing adapters
are ligated, samples can be pooled into a single tube for MPS (see
below).
Approach 2: for hereditary breast cancer (2 genes: BRCA1,
BRCA2 - 111 amplicons) and familial aorta aneurism (3 genes:
FBN1, TGFBR1, TGFBR2 - 110 amplicons) two consecutive
rounds of PCR were applied. In this approach adapter ligation is
replaced by a second PCR step.
During the first PCR, gene-specific amplicons are generated,
using primers modified at their 59 end with a universal M13 linker
sequence. In the first experiments (2 out of 10 experiments), we
equimolarly pooled singleplex reactions. In further experiments the
first amplification step was replaced by a multiplex PCR in which
several amplicons of the same patient are combined (we typically
aimed for 10-plex PCR reactions) to reduce the workload and
consumable cost. After 1/1000 dilution of the PCR products, a
second round of PCR is performed. In the second PCR, primers
containing the common A or B sequence, a patient specific barcode
sequence (MID) and a universal linker sequence (M13) were used to
amplify the initial PCR products, thereby extending them with the
sequences that are required to initiate sequencing and to distinguish
reads from the different patients. Primer sequences, reaction
conditions and constitution of the multiplex reactions are described
by De Leeneer et al. [8] and Baetens et al. [9].
Pooling prior to sequencing. PCRs prior to pooling were
performed in the presence of a saturating dye (LCgreen+, Idaho
Technology Inc) on a real-time PCR instrument (CFX384, Bio-
RAD). PCRs were normalized and equimolarly pooled in relation
to the RFU data (endpoint fluorescence). This pool was purified on
a High Pure PCR Cleanup Micro kit (Roche).
During optimization of the multiplex reactions FAM labeled
MID primers were used to evaluate equimolarity between
amplicons within one reaction and fluorescent peaks were
separated on an ABI3730 capillary system.
Sequencing reaction and data analysis
Emulsion PCR and sequencing reactions on the GS-FLX (454-
Roche) were performed according to the manufacturer’s instruc-
tions. On average 380,000 (range: 290,000–520,000) reads were
obtained in a standard GS-FLX run and 1,000,000 when the
Titanium chemistry was used (range: 800,000–1,200,000). In each
experiment, a minimum of 90% of all reads mapped to the
reference sequence. FASTA files were analyzed with the in house
developed variant interpretation pipeline (VIP) software (version
1.3) [10].
Distribution plots and log-normal curve fitting were performed
using the GraphPad PRISM 5 software. Statistical analysis of the
potential bias introduced during emulsion PCR and pyrosequenc-
ing was performed using the R package. The mean of both relative
coverages (obtained after sequencing on the GS-FLX) and relative
fluorescent signals (obtained on capillary electrophoresis on an
ABI3730) was used to center both data sets for each multiplex
prior to principal component analysis to remove the effect of the
different multiplex sizes.
Results
Calculation of coverage depth in function of sensitivity
With Sanger sequencing a two-fold (forward and reverse)
coverage is considered to be sufficient for molecular diagnostics,
provided that sequences are of high quality. At this moment there is
no clear consensus on the required minimum coverage (MC) to
reliably detect heterozygous variations using MPS technologies.
Current guidelines typically suggest a 20-fold coverage [11], with
little justification on the proposed value or how it would require
adjustment depending on sequencing and analysis procedures or
context. Because MPS is based on the sequencing of single, clonally
amplified molecules, sampling effects need to be taken into account
at low coverage. At one fold coverage there is a 50% chance to
detect a heterozygous variant and a 50% (1/2
‘1) chance to miss it.
At two fold coverage, there is a 25% chance to detect only the
mutant allele, 50% chance to detect both and 25% (1/2
‘2) to detect
only the wild type allele. Even at 10-fold coverage there is a chance
of about 1/1000 (1/2
‘10) to miss the variant allele completely. Since
data analysis usually involves filtering out low frequency variants to
reduce false positives resulting from sequencing errors (see below),
the minimal number of reads for detection of heterozygous variants
depends on the applied filter settings.
Table 1 shows an overview of the theoretically required minimal
coverage (MC) to reliably detect heterozygous variants at varying
minimum allele frequencies with a given power. Calculations were
based on the following: the interpretation of a specific base has only
two possible outcomes (equal to or different from the reference
sequence). Theoretically, the probability to observe a variant in a
specific number of reads (#Rv) out of all reads for a SAC (total
coverage) can be derived from a binominal distribution with success
probability equal to the expected mutant variant frequency in the
totalnumberofreads(50%forheterozygousvariantswithoutvariant
related alignment errors). The binomial distribution can also be used
to tabulate the cumulative probabilities in function of the total
coverage and the relative variant frequency that is deemed sufficient
to indicate a real variant, i.e. above the filter level below which
variants are thought to be sequencing errors (#Rv/total coverage).
Hence, one can simply look up the coverage that is required for
detecting a heterozygous variant at a minimum defined variant
frequency with a predefined power. This coverage is referred to as
the minimum coverage (MC) for a given SAC. To facilitate
interpretation, power values (P) were converted into scores (Q)
(similar to calculation of PHRED scores [12]): Q=210*log(12P).
Road to Next Generation Molecular Diagnostics
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detect heterozygous variants increases. There is also a strong
dependency on the sequencing error filter level: if only variants
present in 30% of the reads are considered as true variants, a 61-fold
MC is required, while a coverage depth of only 27 is needed if the
filter threshold is lowered to 20% (both for or P=99.90%,
corresponding to a Phred score of 30, required for standard
molecular diagnostics).
When plotting obtained variant frequencies vs. coverage of
unfiltered data, the largest deviations from the binomial
distribution are observed at the lower allele frequencies. Because
the majority of such data points are sequencing errors, especially
related to homopolymers (see below), dispersion can best be
evaluated at frequencies above 50%. Allele specific amplification
biases during sample preparation or emulsion PCR are the most
likely cause of any remaining dispersion. A stepwise analysis
starting from unfiltered variant data in one experiment (9721
variants) to determine the dispersion is shown in Supporting
information Tool S2. We calculated the overall fraction of
heterozygous variants with a frequency deviating from the
expected 50% ratio, and this was estimated to be 10%, after
correcting for sequencing errors being interpreted as heterozygous
variants.
Number of samples per run in function of MC
Determination of the required minimum coverage is not
sufficient to calculate the number of SAC that can be analyzed
with a given number of reads because the coverage may differ
between SAC. In an ideal experiment, all SAC have exactly the
same coverage, matching the theoretically determined required
MC. In practice, some SAC will display a lower coverage than
others. Since these require at least the MC as well, other SAC will
have a higher coverage than absolutely required wasting
sequencing capacity. The correction factor to convert the
minimum coverage into the required average coverage can be
derived from an evaluation of the distribution of the coverage.
Figure 1A plots the distribution of coverage to the number of
SAC and shows that the variation in coverage depth is log
normally distributed. Coverage data of 3300 SAC were used to
generate this plot (3 genes: FBN1, TGFBR1, TGFBR2 for 30
patients). Only at low coverage (,40), the distribution deviates
from its Gaussian fit. This reflects a low number of reactions that
failed to give a normal coverage. By calculating this variation in
coverage depth, one can dictate how many extra reads are needed
to cover all sequences at the required level. By plotting the
cumulative distribution of the fold difference of the mean coverage
to the SAC coverage, one can determine the correction factor by
which the mean coverage needs to be multiplied in order to have a
given fraction of SAC with at least the minimum coverage
(Figure 1b). The value on the X-axis at which the histogram passes
the 90% threshold is defined as the correction factor (F90). More
stringent correction can be obtained by calculating a correction
factor at higher thresholds (e.g. F95).
Supplemental Tool S2 provides an easy to use calculation
template (MS Excel). Based on the coverage obtained in a proof of
principle experiment, one can simply calculate the spread
correction factor and the number of patients that can be screened
Table 1. Overview of the required coverage to detect
heterozygous variants, in function of the desired power (rows)
and the level of filtering being applied (columns).
sequencing error filter level
Power (Q) 5% 10% 15% 20% 25% 30% 35%
90.00% (10) 4 4 4 7 7 12 24
95.00% (13) 5 5 8 8 11 18 30
99.00% (20) 7 7 11 17 19 35 54
9 9 . 5 0 % ( 2 3 ) 81 21 21 82 64 27 1
99.90% (30) 10 14 18 27 38 61 110
99.95% (33) 11 15 19 28 42 68 117
99.99% (40) 14 18 28 34 54 83 148
99.995% (43) 15 19 30 42 61 92 165
100.00% (50) 17 25 36 51 70 109 194
doi:10.1371/journal.pone.0025531.t001
Figure 1. Coverage analysis. A) Distribution plot of the coverage observed in a pilot study representative for NGMD screening (full line) with 3300
sample amplicon combinations (SAC), derived from sequencing 30 patients for FBN1, TGFBR1 and TGFBR2. The coverage across different SAC appears
to be log normally distributed (R
2 with best Gaussian fit (dashed line).0.99). At low coverage (,40, vertical line), the distribution deviates from its
Gaussian fit. This reflects a low number of reactions that failed to give a normal coverage. Analysis of these SAC may provide clues on how to further
optimize the screening. B) Cumulative distribution plot of the relative coverage (expressed as a fold difference of each SAC to the average coverage).
This plot allows determination of the correction factor by looking up the relative coverage for which the curve passes a given threshold, e.g. 90% for
the calculation of F90.
doi:10.1371/journal.pone.0025531.g001
Road to Next Generation Molecular Diagnostics
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25531in a run, ensuring sufficient power to detect heterozygous variants.
The ‘spread correction factor sheet’ calculates the spread
correction factor obtained (see also figure 1B) based on the
coverage of different SAC in an experiment. In the ‘Samples per
screening sheet’, additional requirements like predefined power,
threshold for sequencing error filtering, instrument specifications
and number of amplicons can be filled in. For example, for a
BRCA1/BRCA2 screening of 111 amplicons using P=99.90%,
threshold=25% and spread correction factor 2.5 the tool
determines that 83 samples can be screened in a single GS-FLX
(Titanium chemistry) run with 90% of sequences covered
sufficiently to provide a minimum power of 99.9%. This number
decreases to 65 samples if 95% of the sequences need to be
covered sufficiently.
Emulsion PCR
We assumed a more narrow spread in coverage would be
obtained by sequencing an equimolar pool of fragments or
amplicons. To test the assumption that the emulsion PCR does not
introduce a substantial bias we compared the relative peak
intensities (determined by fragment analysis on ABI3730xl) of 9
different fluorescently labeled multiplex PCRs (6 to 11-plexes),
amplified on 5 different samples (total of 360 SACs) with the
corresponding relative coverage after sequencing. Overall there
Figure 2. emulsion PCR and sequencing bias. Nine different fluorescently labeled multiplex PCRs (6 to 11-plexes), amplified on 5 different
samples, were analyzed on a capillary sequencer to determine relative amplicon abundances prior to emulsion PCR and sequencing on a GS-FLX.
Relative fluorescent signals were compared to their corresponding coverage values. The top panel shows the relative coverage in function of the
relative fluorescence for the 360 SACs. The ellipse represents the 95% confidence region according to the multivariate normal distribution. The
continuous line is the first principal component (PC) which indicates the direction of the largest variance in the sample: 92% of the variance of the
sample can be explained by the first PC. The first PC lays very close to the first bisectrice (dashed line). Hence, there is a good 1:1 relationship
between the relative fluorescence and the relative coverage, indicating that a certain increase in relative fluorescence on average induces an equal
increase in relative coverage. The table at the bottom summarizes results across all 9 multiplex PCRs (360 SACs). It shows that the first PC explains a
large proportion of the variance of each multiplex (84%–98%): the majority of variation in coverage results from variations in input amounts (as
determined by fragment analysis on a capillary sequencer).
doi:10.1371/journal.pone.0025531.g002
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and the relative coverage, indicating that a certain increase in
relative fluorescence on average induces an equal increase in
relative coverage (Figure 2). In contrast to the findings obtained for
shotgun sequencing [13], our data indicate that sequencing bias is
limited and that sequencing cost efficacy can be improved by
generating more equimolar input pools.
Equimolarity can be achieved by optimizing amplification
conditions or by normalizing PCR product concentrations.
Although normalization can potentially increase sequencing
efficiency, one may lose on overall processing efficiency due to
the required effort to normalize the SAC. With good primer
design tools one should be able to get similar DNA quantities (as
measured by end point fluorescence in a qPCR reaction with
saturating DNA binding dye) for the 90% best assays. For such
screenings, the majority of amplicons do not require any
normalization and a significant portion of all remaining amplicons
can be made equimolar by a simple normalization. Figure 3 shows
the distribution of the relative end point fluorescence intensities
(RFU, relative to the maximum fluorescence), across 627 different
qPCR reactions on a single sample amplified for 15 genes
associated with hearing loss. It is important to notice that
comparison of end point fluorescence values is only valid for
singleplex PCR products of comparable length.
Sequence quality analysis
Sequence quality was determined using the GS-FLX basecaller.
Quality scores per base were averaged across all reads within a
single run (,700,000 reads of 1 GS-FLX Titanium experiment for
BRCA1/2 and FBN1, TGFBR1, TGFBR2 amplicons), and plotted
in function of the sequenced base (Figure 4A). Because of the setup
of this amplicon sequencing run, the number of reads longer than
400 bp was too low to provide accurate quality estimations in that
range. Quality scores (Q) were converted into probabilities of
erroneous basecalls (P) as follows: P=10‘(2Q/10), corresponding
to the better known Phred scores.
Pyrosequencing reactions are characterized by a low false call
rate for substitutions, but also by a higher error rate for insertions
and deletions – especially in homopolymeric regions [14]. A
combination of quality and allele frequency filters may eliminate
most errors, but fails to distinguish real insertions/deletions from
sequencing errors in case of longer homopolymers (7 or more
repeats) (Figure 4B).
Discussion
As massively parallel sequencing has the ability to become the
standard for next generation molecular diagnostics, more insight
is urgently needed in the limitations of the technology and tools
are required to standardize the quality of the diagnostic tests
offered in various laboratories. In this study, we thoroughly
evaluated data obtained with 10 GS-FLX experiments allowing
us to shed light on a number of important issues and provide
workarounds.
Current massively parallel sequencers offer a throughput per
run that is insufficient for complete genome sequencing at
affordable cost in a diagnostic setting, but mostly supersedes the
requirements for targeted resequencing of single DNA samples.
Strategies for next generation molecular diagnostics will therefore
have to deal with both the selection of regions of interest and
with sample multiplexing. Regions can be selected by either
hybridization based enrichment or PCR amplification. Enrich-
ment by capturing DNA fragments on oligonucleotides – on
array (e.g. NimbleGen, Febit) or in solution (e.g. Agilent,
Illumina) – has the advantage that many regions can be targeted
in parallel (target multiplexing). While this allows enrichment of a
high number of regions of interest (up to an entire human
exome), it is well known to introduce large variations in coverage
[15,16]. In addition, enrichment is rarely complete: some regions
are not captured whereas other unwanted regions may be
copurified. The main drawbacks of this technology for molecular
diagnostics are its high cost and the large quantities of high
quality DNA that are required. Commercially available sample
preparation approaches like Raindance, Fluidigm Acces array or
more recently Haloplex PCR can increase throughput tremen-
dously, but are less cost efficient for smaller experiments. Using
the more classical approach of small scale, self-designed PCR
assays has the advantage that the same set-up as for Sanger
sequencing can be maintained, facilitating confirmation of the
detected mutations afterwards. For these reasons, we evaluated
the latter for NGMD.
Sample multiplexing can be achieved by physically separating
samples in the sequencing reaction or by tagging the amplicons
with different sample specific sequences during library prepara-
tion. Physical separation on current MPS instruments offers
limited flexibility in the number of samples to be multiplexed (up
to 16 in GS-FLX) and may reduce the available sequencing
capacity by blocking parts of the available sequencing space.
Therefore, a sample tagging approach is preferred. For applica-
tions where different samples are analyzed for different genes, no
special multiplexing modifications need to be done when
sequences can be easily attributed to the different samples based
on correct alignment to the gene of interest. Four major
amplification based approaches for NGMD are currently used
worldwide: 1) PCR with fusion primers (GS-FLX), 2) PCR
followed by adapter ligation (GS-FLX), 3) two consecutive rounds
of PCR (GS-FLX), and 4) shearing of concatenated PCR pro-
ducts followed by adapter ligation (various MPS platforms).
It must be noted that other approaches or variations on the
methods described may be used as well. In this study, we evaluated
Figure 3. Analysis of amplicon abundance. This graph represents
the distribution of the relative end point fluorescence intensities (RFU,
relative to the maximum fluorescence), across 627 different qPCR
reactions on a single sample. About 90% of reactions have RFU values
of at least 0.5. This implies that if equal volumes of all PCR reactions are
pooled, the concentration of 90% of amplicons will vary less than 2-fold.
This fraction of amplicons can be increased to 96% by using a double
volume for the PCRs in the 0.5–0.25 RFU range, and to 97% by using a
quadruple volume for the PCRs in the 0.25–0.125 RFU range. The
concentration of the remaining 3% of PCR reactions is too low to be
efficiently used.
doi:10.1371/journal.pone.0025531.g003
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simplicity and ease of set-up. The drawback is the large number of
individual PCR reactions that need to be performed. Hence, we
concluded that this approach is best suited if a screening only
needs to be performed a few times or when results are quickly
required and one cannot afford optimization. As soon as a few
hundred samples need to be screened, approach 3 may be the
preferred alternative. By multiplexing PCR reactions in approach
3, one can reduce the workload and consumable cost for sample
preparation. Although optimization of multiplex PCR may be
challenging, there is a good return in increased efficiency (in
terms of cost and workload to prepare samples) for tests that will
be run many times – as is the case in diagnostic sequencing.
Further optimization may be achieved if the first and second
round of PCR can be combined into a single PCR containing the
two types of primers (inner target specific and outer sample
specific primers).
Because of fundamental differences between the traditional and
the so called next-generation sequencing methods, people are
uncertain on how to deal with coverage and how to interpret
variants, errors and quality scores. Despite the availability of some
guidelines on required coverage provided by sequencing instru-
ment suppliers, there was no theoretical framework to actually
calculate the required minimum coverage. We here provide such a
framework and implement it into a spreadsheet template that can
be used to determine the required coverage and the number of
patients that can be screened in a single run.
A number of sources of false positives and false negatives are
identical for both Sanger and massively parallel sequencing and
hence independent on the fold coverage. However, because MPS
is based on the sequencing of single, clonally amplified molecules
and uses a completely different sequencing chemistry, new types of
error sources must be taken into account. Knowing the possible
sources of error, one may optimize sample preparation and
sequencing protocols, and take measures to adjust the data analysis
pipeline for these new types of errors.
Table 1 shows an overview of the theoretically required MC to
reliably detect heterozygous variants at varying minimum allele
frequencies with a given power. Note that this theoretical MC
value only accounts for allelic drop out due to sampling effects and
that it should be treated as a lower limit for the actual MC that
may be larger because of additional variation affecting allele
frequencies. Because of inter-lab variation we cannot propose a
single value for the required minimum coverage, but labs can
determine their own MC value based on their sequencing error
rate (filter setting) and the required power to detect variants
(Table 1, Supplemental Tool S1). When new to NGMD, filtering
at 25% and aiming for 99.9% power (resulting in an MC of 38)
may be a good starting point. A 5-fold coverage is expected to be
sufficient to tolerate occasional sequencing errors when screening
for homozygous variations only.
Based on the strategies and methods described in this paper we
successfully developed and validated the screening of the complete
coding region of the BRCA1 and BRCA2 genes in a diagnostic setting
[8], demonstrating the feasibility of performing more efficient
molecular diagnostics using massively parallel sequencing. The
application of massive parallel sequencing for clinical sequencing of
BRCA1/2 on the Illumina GAII has been recently described [17,18].
We agree with Morgan et al., that the major remaining hurdle is the
availability of data analysis tools that provide the required high
quality for in-vitro diagnostics and that are really tailored towards a
routine diagnostic setting. The availability of commercial software
packages and the advent of smaller scaled MPS instruments such as
the GS-Junior and Illumina Miseq and the development of the so-
called third generation sequencers like Ion Torrent are expected to
push this new sequencing technology into the field of diagnostics,
starting with the multigenic disorders for which there are no good
alternativesavailableatthismoment.However,becauseofitsproven
track record, its superior flexibility and its large install base, Sanger
sequencing is unlikely to be replaced in the near future for smaller
screening projects and it will remain a valuable technology for
confirmation of mutations observed by other technologies.
Figure 4. GS-FLX sequence quality analysis. a) Average quality score in function of the position within the reads for a representative dataset
(full Titanium run with amplicons for breast cancer and for familial aorta aneurysmata screenings). Across the first 400 bp there is an average quality
of 35.3 corresponding to a predicted error rate of 0.029%. b) Comparison of the observed homopolymer length in a series of sequencing runs to the
expected length based on the reference sequence. Results are plotted as the fraction of reads having correct homopolymer length estimation (n), an
underestimation of the homopolymer length (n21, n22, n23) or an overestimation (n+1, n+2, n+3). The vast majority of reads for homopolymers of
up to 6 repeats has correct length estimation, less than 2% are overcalls and less than 10% are undercalls. For homopolymers of 7 repeats, three
quarters of the reads are correctly called and over 20% of the reads are interpreted to be missing one repeat. Only by filtering for low allele
frequencies can these repeats be analyzed. At 8 repeats only about half of the reads are correctly called, at even larger homopolymer lengths only a
minority of reads have a correct basecalling.
doi:10.1371/journal.pone.0025531.g004
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